Comparative Analysis of National Drug Policies - Second Workshop Geneva, 10-13 June 1996 - EDM Research Series No. 025
(1997; 175 pages) View the PDF document
Table of Contents
View the documentExecutive summary
View the documentI. Introduction
Open this folder and view contentsII. Background on the research project
Open this folder and view contentsIII. Second workshop
Open this folder and view contentsIV. Preliminary findings
Close this folderV. Conclusions of the workshop and follow-up plans
View the document1. Main outcomes
View the document2. Next steps
Open this folder and view contentsAnnex 1: Research proposal
View the documentAnnex 2: List of participants
View the documentAnnex 3: Agenda
View the documentAnnex 4: Questionnaire on NDP performance assessment
Open this folder and view contentsAnnex 5: Achievements of the national drug policies in the 12 countries
View the documentAnnex 6: Consolidated tables
View the documentOther documents in the DAP Research Series

1. Main outcomes

The workshop ended with considerable enthusiasm among all participants about the results achieved during the few days of the meeting; country teams and coordinators felt that the workshop had been a very important step in the research and was key for its continuation.

In summary, the workshop:

• provided one of the first occasions for countries to compare data collected in a standardized way. It showed the importance of having good methods and data and justified the WHO strategy of providing standardized methods for both national assessment and cross national comparison;

• permitted the review of the indicators and the political mapping as methods of policy analysis and assessments of NDP (field testing) and resulted in some improvements which will be incorporated in the next edition;

• allowed countries to share experiences in order to develop better approaches for policy formulation and implementation. Although there is no standard recipe for improving the policy process in countries, the workshop did come up with some useful conclusions;

• began the process of identifying specific strengths and weaknesses of existing policy from national and cross national perspectives; of generating hypotheses to explain how different pharmaceutical policies can affect the performance of the pharmaceutical sector; and of identifying specific policy innovations;

• showed the necessity to develop such research in countries with different socio-economic background; and to set up sustainable NDP monitoring systems in most countries;

• finally, enhanced the research capabilities of all the participants of the 12 countries.

to previous section
to next section
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: December 6, 2017